CERo Therapeutics CER-1236 Trial Update
Analysis based on 6 articles · First reported Jun 15, 2026 · Last updated Jun 15, 2026
The positive clinical update from Coeptis Therapeutics Holdings' CERTAIN-T trial, particularly the observed clinical improvement and lack of dose-limiting toxicities for CER-1236, is likely to generate positive sentiment for Coeptis Therapeutics Holdings and potentially other companies in the cellular immunotherapy sector. The expansion of the trial to include additional myeloid disease settings also suggests broader market potential for the therapy.
Coeptis Therapeutics Holdings announced a positive clinical update from its ongoing Phase 1 CERTAIN-T clinical trial for CER-1236, an engineered T cell therapeutic for hematologic malignancies. The company reported encouraging findings, including a patient with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation after treatment, and clinical improvement in two patients. No cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, dose-limiting toxicities, or treatment-related severe adverse events were observed. Coeptis Therapeutics Holdings has treated six patients and initiated the third planned cohort, which will include patients with myelodysplastic syndromes and myelofibrosis, and will evaluate a higher dose level.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard